Home
BioAge Labs

BioAge Labs Market Share Analysis for August 2026

We are building a pipeline of therapies to treat cardiometabolic disease by targeting the biology of human aging.

Health > Biotechnology and Pharmaceuticals

Domainbioagelabs.com

Year Founded2015

Employees51 - 200

Annual Revenue$5M - $10M

BioAge Labs

BioAge Labs (including company regionals)

bioagelabs.com

See more website traffic and engagement information

BioAge Labs Revenue up to August 2026 is 5M - 10M

revenue generated by BioAge Labs top domains

BioAge Labs top domains revenue over 3 years

Revenue for BioAge Labs top domains

bioagelabs.com5M - 10M

See more with Sales Intelligence

Total visits to BioAge Labs's top domains

Understand BioAge Labs market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

bioagelabs.com9.3K

See more with Sales Intelligence

Avg. visit duration in BioAge Labs's top domains

Analyze BioAge Labs engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

bioagelabs.com00:01:00

See more with Sales Intelligence

Avg. pageviews on BioAge Labs's top domains

See how BioAge Labs keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

bioagelabs.com2.14

See more with Sales Intelligence

BioAge Labs top competitors by domain

Top similar sites in August 2026, ranked by their affinity

biopharmadive.comCompany NameBioPharma DiveEmployees51 - 200HQUnited States, Washington, WashingtonAnnual revenue$10M - $15MTotal visits191.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by BioAge Labs

These are the website technologies, by industry, used by BioAge Labs top domains

Content Management System (2)

Medium

Mobile (2)

Meta Viewport

Advertising (1)

PubMatic

Audio Video Media (1)

SimpleCast

More Technologies

6

See all

News & Signals from BioAge Labs

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBioAge Labs, Inc. had revenue of $2.45M on Sep 5th '26.* BioAge reported a quarterly loss of $0.58 per share, better than the expected $0.65 loss, on $2.45 million in revenue.

NewsBioAge Labs, Inc. is developing BGE-102.BioAge is testing BGE-102 in the phase 2 Quell-Cv trial in patients at elevated cardiovascular risk and plans a phase 1b/2a study in diabetic macular edema.

NewsHitGen Ltd partnered with BioAge on Apr 1st '21.The collaboration between HitGen and BioAge has previously resulted in the successful identification of promising hit molecules announced in April 2021, a joint publication in Bioorganic & Medicinal Chemistry Letters in February 2024 entitled "The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening", and joint patent filings covering the structurally novel compounds discovered through the DEL screening process.